Inhibition of complement activation by pexelizurnab reduces death and myocardial infarction in cardiac surgical patients with selected risk profiles: Results from the international multi-center PRIMO-CABG study
Publication
, Conference
Haverich, A; Taylor, KM; Carrier, M; Chen, JC; Sherman, SK; Van de Werf, F; Newman, MF; Levy, JH; Adams, PX; Todaro, TG; van der Laan, M; Verrier, ED
Published in: CIRCULATION
October 26, 2004
Duke Scholars
Published In
CIRCULATION
EISSN
1524-4539
ISSN
0009-7322
Publication Date
October 26, 2004
Volume
110
Issue
17
Start / End Page
421 / 421
Location
New Orleans, LA
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Conference Name
77th Scientific Meeting of the American-Heart-Association
Related Subject Headings
- Cardiovascular System & Hematology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Haverich, A., Taylor, K. M., Carrier, M., Chen, J. C., Sherman, S. K., Van de Werf, F., … Verrier, E. D. (2004). Inhibition of complement activation by pexelizurnab reduces death and myocardial infarction in cardiac surgical patients with selected risk profiles: Results from the international multi-center PRIMO-CABG study. In CIRCULATION (Vol. 110, pp. 421–421). New Orleans, LA: LIPPINCOTT WILLIAMS & WILKINS.
Haverich, A., K. M. Taylor, M. Carrier, J. C. Chen, S. K. Sherman, F. Van de Werf, M. F. Newman, et al. “Inhibition of complement activation by pexelizurnab reduces death and myocardial infarction in cardiac surgical patients with selected risk profiles: Results from the international multi-center PRIMO-CABG study.” In CIRCULATION, 110:421–421. LIPPINCOTT WILLIAMS & WILKINS, 2004.
Haverich A, Taylor KM, Carrier M, Chen JC, Sherman SK, Van de Werf F, et al. Inhibition of complement activation by pexelizurnab reduces death and myocardial infarction in cardiac surgical patients with selected risk profiles: Results from the international multi-center PRIMO-CABG study. In: CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2004. p. 421–421.
Haverich, A., et al. “Inhibition of complement activation by pexelizurnab reduces death and myocardial infarction in cardiac surgical patients with selected risk profiles: Results from the international multi-center PRIMO-CABG study.” CIRCULATION, vol. 110, no. 17, LIPPINCOTT WILLIAMS & WILKINS, 2004, pp. 421–421.
Haverich A, Taylor KM, Carrier M, Chen JC, Sherman SK, Van de Werf F, Newman MF, Levy JH, Adams PX, Todaro TG, van der Laan M, Verrier ED. Inhibition of complement activation by pexelizurnab reduces death and myocardial infarction in cardiac surgical patients with selected risk profiles: Results from the international multi-center PRIMO-CABG study. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2004. p. 421–421.
Published In
CIRCULATION
EISSN
1524-4539
ISSN
0009-7322
Publication Date
October 26, 2004
Volume
110
Issue
17
Start / End Page
421 / 421
Location
New Orleans, LA
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Conference Name
77th Scientific Meeting of the American-Heart-Association
Related Subject Headings
- Cardiovascular System & Hematology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology